Skip to main content
Journal cover image

Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure

Publication ,  Conference
Smith, WB; Russell, S; Ghali, JK; Painchaud, CA; Ghazzi, MM; Konstam, MA; Udelson, JE; Selaru, P
Published in: EUROPEAN HEART JOURNAL
September 1, 2001

Duke Scholars

Published In

EUROPEAN HEART JOURNAL

ISSN

0195-668X

Publication Date

September 1, 2001

Volume

22

Start / End Page

541 / 541

Publisher

W B SAUNDERS CO LTD

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smith, W. B., Russell, S., Ghali, J. K., Painchaud, C. A., Ghazzi, M. M., Konstam, M. A., … Selaru, P. (2001). Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure. In EUROPEAN HEART JOURNAL (Vol. 22, pp. 541–541). W B SAUNDERS CO LTD.
Smith, W. B., S. Russell, J. K. Ghali, C. A. Painchaud, M. M. Ghazzi, M. A. Konstam, J. E. Udelson, and P. Selaru. “Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure.” In EUROPEAN HEART JOURNAL, 22:541–541. W B SAUNDERS CO LTD, 2001.
Smith WB, Russell S, Ghali JK, Painchaud CA, Ghazzi MM, Konstam MA, et al. Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure. In: EUROPEAN HEART JOURNAL. W B SAUNDERS CO LTD; 2001. p. 541–541.
Smith WB, Russell S, Ghali JK, Painchaud CA, Ghazzi MM, Konstam MA, Udelson JE, Selaru P. Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure. EUROPEAN HEART JOURNAL. W B SAUNDERS CO LTD; 2001. p. 541–541.
Journal cover image

Published In

EUROPEAN HEART JOURNAL

ISSN

0195-668X

Publication Date

September 1, 2001

Volume

22

Start / End Page

541 / 541

Publisher

W B SAUNDERS CO LTD

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology